RAPT Therapeutics, Inc.
Clinical trials sponsored by RAPT Therapeutics, Inc., explained in plain language.
Develops oral small-molecule therapies for inflammatory diseases and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could let food allergy sufferers eat peanuts and milk safely Results expected Apr 2027 (estimated)
-
New asthma pill shows promise in early trial
Disease control Stopped earlyThis phase 2 study tested an experimental oral drug called RPT193 in 38 adults with moderate-to-severe asthma that was not fully controlled by standard inhalers. The goal was to see if RPT193 could reduce asthma attacks and improve lung function. The trial was terminated early, s…
Phase 2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New eczema pill shows promise in Mid-Stage trial
Symptom relief Stopped earlyThis study tested an experimental daily pill called RPT193 for adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve with topical creams. The goal was to see if it reduces skin redness, swelling, and itchiness over 16 weeks. The trial involved 229 particip…
Phase 2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC